Transcatheter Mitral Valve Market Seen Reaching $2.49 Billion by 2030

The transcatheter mitral valve market is projected to grow from $1.61 billion in 2025 to $1.76 billion in 2026, with North America leading and Asia-Pacific set for the fastest growth. Rising cardiovascular disease, aging populations and wider use of minimally invasive cardiac procedures are driving demand.

Why it matters: - The transcatheter mitral valve market is expanding as hospitals and cardiology teams look for less invasive alternatives to open-heart surgery. - Growth matters most for high-risk patients with mitral valve disease who may not be strong candidates for traditional surgical repair or replacement. - Rising cardiovascular disease rates are likely to increase demand for advanced valve therapies over the next several years.

What happened: - The market is projected to rise from $1.61 billion in 2025 to $1.76 billion in 2026, a 9.3% compound annual growth rate. - The market is expected to reach $2.49 billion by 2030, growing at a 9.0% CAGR during the forecast period. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing regional market over the forecast period. - The report covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa in addition to North America and Asia-Pacific. - The Business Research Company released the 2026 report on the transcatheter mitral valve market with updated forecasts and market analysis. - Download a free sample of the report - View the full market report

The details: - Market growth has been supported by limited availability of transcatheter mitral valves, continued reliance on surgical valve replacement, higher awareness of mitral valve disease and more hospital cardiac procedures. - Early adoption among high-risk patient populations also contributed to the market's recent expansion. - Forecast growth is expected to be supported by valve design innovation, a larger elderly population, more cardiac catheterization labs, higher healthcare spending and broader acceptance of minimally invasive cardiac interventions. - The report points to rising cardiovascular disease as a key driver. - National Center for Biotechnology Information data released in August 2025 projects a 90.0% increase in cardiovascular disease prevalence between 2025 and 2050, along with higher mortality and disability rates. - Transcatheter mitral valves offer a less invasive way to repair or replace damaged valves, improve blood flow and heart function, and reduce symptoms. - The approach is especially relevant for patients considered high-risk for open-heart surgery. - Device innovation includes self-expanding and balloon-expandable valves, plus edge-to-edge and chordal repair devices. - Imaging and navigation technologies are improving procedural precision and safety.

Between the lines: - North America's lead suggests the market is already benefiting from advanced healthcare infrastructure, strong clinical adoption and ongoing research activity. - Asia-Pacific's faster growth points to rising healthcare investment and broader awareness of minimally invasive cardiovascular treatments. - The report's added tools, including TAM analysis, company scoring matrices, forecasting dashboards and market hotspot infographics, indicate a stronger focus on competitive positioning and near-term opportunity mapping.

What's next: - Market growth is likely to continue as the patient pool expands and more centers add catheter-based structural heart capabilities. - Wider use of advanced imaging and newer valve platforms could broaden eligibility and improve outcomes. - The market's regional momentum will likely stay strongest in North America and Asia-Pacific, with other global regions adding incremental growth. - Follow the company on LinkedIn